Free Trial
→ Is Elon's empire crumbling? (From Brownstone Research) (Ad)
NASDAQ:SNPX

Synaptogenix 5/15/2024 Earnings Report

Synaptogenix logo
$6.22 +0.33 (+5.60%)
As of 08/6/2025
ProfileEarnings History

Synaptogenix EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Date
5/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Synaptogenix's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Synaptogenix Earnings Headlines

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today
July 1, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-formerly-synaptogenix-begins-trading-under-new-nasdaq-stock-symbol-taox-effective-at-market-open-today-302495716.html
Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy
June 26, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-announces-name-change-to-tao-synergies-and-new-ticker-symbol-taox-for-alignment-with-ai-focused-crypto-treasury-strategy-302491852.html
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
August 8 at 2:00 AM  |  Porter & Company (Ad)
Synaptogenix begins TAO acquisition as part of crypto treasury strategy
June 26, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/synaptogenix-begins-tao-acquisition-as-part-of-crypto-treasury-strategy-93CH-4144284
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking
June 24, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-announces-initial-tao-acquisition-under-crypto-treasury-strategy-appoints-bitgo-as-custodian-and-commences-yield-generation-through-staking-302489342.html
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token
June 9, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/synaptogenix-appoints-crypto-expert-to-lead-digital-asset-treasury-strategy-focused-exclusively-on-top-valued-ai-token-302476176.html
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:SNPX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

View Synaptogenix Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles